INTRODUCTION
The p53 upregulated modulator of apoptosis (PUMA) is a member of the BH3-only protein family and has been known as an essential apoptosis inducer for many years (Chipuk et al., 2005; Vousden, 2005; Yu and Zhang, 2003) . The apoptosisinducing activity of PUMA has been shown in different cell types, such as mouse embryonic fibroblasts, developing neurons, lymphocytes, tumor cells, and intestinal progenitor/stem cells (Michalak et al., 2010; Villunger et al., 2003) . Due to its potent apoptotic activity, PUMA has received considerable research interest and has been considered as an important therapeutic candidate gene for the prevention and treatment of cancer and degenerative diseases (Ito et al., 2005; Yu, 2009) .
Despite many years of intensive studies on PUMA, outstanding questions remain. Numerous studies have shown that enhanced PUMA expression is not always linked to apoptosis. Interaction of human umbilical vein endothelial cells (HUVECs) with monocytes increased PUMA protein level in the former (Gawad et al., 2009 ), yet the elevated PUMA protein level did not result in apoptosis of the cells (Gawad et al., 2009) . In brain ischemia, PUMA expression was markedly upregulated (Kuroki et al., 2009 ). However, apoptosis was not increased, and the brain stroke volume was unchanged in the Puma-deficient mice (Kuroki et al., 2009 ). The biological consequences of such increased PUMA expression remain thus far unclear, indicating potentially unknown functions of PUMA other than induction of apoptosis. In addition, studies have shown that the proapoptotic action of PUMA may be cell specific. For example, although Puma deficiency reduced apoptosis in intestinal progenitor/ stem cells, it did not affect apoptosis of endothelial cells (Qiu et al., 2008) . Moreover, PUMA is highly expressed in vascular and microglia cells (Tables S1 and S2 ), yet it has not been shown to induce apoptosis in these cells thus far. Instead, little is known about the function of PUMA in vascular and microglia cells. Of note, PUMA was recently reported to be required for tumor development, whereas Noxa, another proapoptotic gene of the BH3-only protein family, inhibited tumorigenesis (Labi et al., 2010; Michalak et al., 2010; Qiu et al., 2011) , demonstrating a distinct proliferative effect of PUMA compared with the other Microglia are resident macrophages of the CNS. Although the immune function of microglia has been widely studied, their role in angiogenesis is not well understood. Some studies reported an angiogenic effect of microglia (Checchin et al., 2006; Liu et al., 2005; Yamaguchi et al., 2011) , whereas others reported an antiangiogenic effect (Stefater Iii et al., 2011) . Interestingly, in the developing mouse retina, the microglia density increases during the first postnatal week and decreases gradually (Santos et al., 2008) . The appearance of retinal microglia precedes and overlaps with the formation of retinal blood vessels, indicating a potential role of microglia in retinal angiogenesis. Further studies are needed to better understand the function of microglia in blood vessel growth.
In the present study, we investigated the effect of PUMA on vascular and microglia cells. We provide evidence that PUMA is an angiogenic factor critically required for the proliferation and survival of vascular and microglia cells by modulating autophagy. At the molecular level, we revealed that PUMA plays a crucial role in regulating Erk activation and intracellular calcium level. Our data revealed an unexpected function of PUMA as an angiogenic factor by promoting survival and proliferation, which contradicts its known role as an essential apoptosis inducer.
RESULTS

PUMA Is Expressed by Retinal Microglia and Blood Vessels
Although PUMA has been intensively studied for many years, its role in the retina remains unexplored. Therefore, we investigated the retinal expression pattern of PUMA. Real-time PCR displayed a postnatal increase in PUMA expression and a subsequent decrease after postnatal day 18 (P18) ( Figure 1A ). This was confirmed at the protein level by western blot ( Figure 1B ). Immunofluorescence staining detected abundant PUMA expression in blood vessels ( Figure 1C ) and CD11b + microglia in the developing mouse retinae ( Figure 1D ). PUMA expression was also identified in primary retinal microglia isolated from neonatal mice ( Figure 1D ). Notably, PUMA expression levels in the developing mouse retinae coincided with the time window of retinal blood vessel development, which occurs mainly within the first postnatal 2 weeks. Moreover, the retinal PUMA expression levels paralleled the time window of the emergence of retinal microglia cells, the number of which increases in the retina during the first postnatal week and decreases gradually thereafter (Santos et al., 2008) . In neonatal mice, the retinal microglia cells are mainly present in the retinal ganglion cell (RGC) layer and the inner nuclear layer (INL) (Santos et al., 2008) , where PUMA expression is abundant ( Figure 1C ). Thus, even though the changes in retinal PUMA expression ( Figures 1A and 1B ) may reflect changes in PUMA expression in retinal neurons, the spatiotemporal correlation of the expression level and distribution of PUMA with retinal blood vessel formation and the appearance and location of retinal microglia cells suggest a potential effect of PUMA on retinal microglia and blood vessels.
Puma Deficiency Decreased Microglia and Blood Vessel Density in the Retina
We subsequently investigated the role of PUMA in the retina using Puma-deficient mice. Because PUMA is known as an essential apoptosis inducer (Chipuk et al., 2005; Vousden, 2005; Yu and Zhang, 2003) , we hypothesized that Puma deficiency might lead to decrease apoptosis in the retina. Surprisingly, we found a marked decrease of retinal microglia numbers in the Puma-deficient mice ( Figures 1E, 1F , S1A, and S1B). Importantly, loss of one Puma allele, i.e., loss of half of its normal expression level ( Figure S1C ), decreased retinal microglia density at different time points (Figures S1D-S1F). Puma deficiency also decreased retinal blood vessel branch points, vessel areas, and diameter (Figures 1F, S1G, and S1H).
To further verify these findings, we intercrossed Puma-deficient mice with Cx3cr1 GFP/+ transgenic mice, in which microglia are GFP labeled (GFP expression under the control of a Cx3cr1 promoter) with a normal density and morphology (Davalos et al., 2005) . We found that the retinal microglia and blood vessel densities decreased in the Puma-deficient Cx3cr1 GFP/+ mice at different time points (Figures 1G and S1I) . The decreased retinal blood vessel branch points, vessel areas, and diameters were also observed in the retinae of 6-month-old Puma-deficient mice ( Figure 1H ). We next investigated microglia and blood vessel density in the brains of Puma-deficient mice to verify whether the effect of PUMA was retina specific. We found reduced microglia ( Figure S1J ) and blood vessel density in the brains of Puma-deficient mice as well ( Figure S1K ). (H) In 6-month-old Puma-deficient mice, retinal blood vessel (IB4 + , green) branch points, vessel areas, and diameters were decreased (n = 7, p < 0.001 or 0.01).
Scale bars represent 50 mm (C, upper; D, F, G); 20 mm (C, lower); 200 mm (E); or 100 mm (H). Data are represented as mean ± SEM; **p < 0.01, ***p < 0.001. See also Figure S1 and Tables S1, S2 , and S3.
Puma Knockdown by Small Hairpin RNA Reduced Microglia and Blood Vessel Density in the Retina The observation of decreased microglia and blood vessel density in the Puma-deficient retina and brain was unexpected, given the known apoptotic activity of PUMA (Chipuk et al., 2005; Vousden, 2005; Yu and Zhang, 2003) . To substantiate our findings, we performed a loss-of-function assay using Puma small hairpin RNA (shRNA). Intravitreal injection of mouse Puma shRNA at P1 decreased PUMA expression level by about 60% in the retinae ( Figures S2A and S2B ) and decreased retinal microglia number, blood vessel branch points, and vessel areas at P6 (Figure 2A ).
Puma Deficiency Did Not Affect Retinal Astrocytes or Decrease Retinal Thickness Because retinal astrocytes are known to contribute to retinal angiogenesis, we investigated whether Puma deficiency affected the retinal astrocyte network and found no significant difference in astrocyte area or morphology between wild-type and Pumadeficient retinae ( Figure S2C ). We further assessed vascular endothelial growth factor (VEGF) expression levels in Puma-deficient and wild-type retinal astrocytes and found a slightly higher VEGF protein level in Puma-deficient astrocytes ( Figure S2D ). Figure S2 and Table S3 .
Clodronate Liposome (CL)
Similarly, real-time PCR and western blot showed that VEGF expression level was somewhat higher in the Puma-deficient retinae (Figures S2E and S2F) . Thus, the vascular defects in the Puma-deficient retinae were unlikely due to a potential astrocyte or VEGF defect.
Loss of retinal neurons can subsequently lead to loss of retinal blood vessels (Zheng et al., 2007) . We next investigated whether Puma deficiency resulted in retinal neuronal loss, which could in turn explain the angiogenesis defect. We measured the thickness of the retinal layers where the retinal blood vessels exist, i.e., the RGC layer, the inner plexiform layer (IPL), and the INL. We found no significant difference in the thickness of the retinal layers before birth at E18 ( Figure S2G ). After birth, in Puma-deficient mice, the thicknesses of the RGC, IPL, INL, and the whole retina were increased ( Figures S2H-S2J ). There was no significant difference in the thickness of the other retinal layers in Puma-deficient mice (data not shown). Moreover, PUMA overexpression in the retinal ganglion cell line (RGC5) markedly induced apoptosis ( Figures S2K-S2M ), consistent with the in vivo observation that Puma deficiency increased thickness of the retinal ganglion cell layer ( Figures S2H-S2J ). In summary, Puma deficiency did not lead to retinal neuronal loss.
To address whether the effect of PUMA on retinal microglia and blood vessels was a common event of the BH3-only protein family genes, we utilized Noxa-deficient mice. Like PUMA, Noxa is also a p53-upregulated proapoptotic gene of the BH3-only protein family. However, no significant microglia or vascular defects were observed in Noxa-deficient mice ( Figure S2N ), demonstrating a functional uniqueness of PUMA.
Retina Microglia Cells Are Required for Retinal Angiogenesis
Microglia cells are present in the mouse retina as early as at embryonic day 11.5 (E11.5) (Santos et al., 2008) , before the mouse retinal vasculature starts to develop at postnatal day 1 (P1). Because the observed retinal microglia cell defect precedes the retinal blood vessel defect in the Puma-deficient mice, we hypothesized that microglia loss in the Puma-deficient retinae might relate to the vascular defect. To test this, we depleted the mouse retinal microglia at P1 (a time point when retinal angiogenesis just begins) by intravitreal and intraperitoneal injection of clodronate liposomes, which reduced retinal microglia numbers by about 50% ( Figure 2B ). Microglia depletion decreased retinal blood vessel branch points and vessel areas ( Figure 2B ), demonstrating that retinal microglia are required for retinal angiogenesis. Consistently, real-time PCR showed that isolated primary retinal microglia expressed numerous angiogenic factors ( Figure 2C ). Importantly, Puma deficiency by genetic deletion or shRNA knockdown markedly decreased the expression of many proangiogenic genes in primary retinal microglia in vitro and in the retina in vivo ( Figures 2D and 2E ). Vice versa, overexpression of PUMA upregulated the expression of some angiogenic genes ( Figure 2F ). Western blot confirmed the downregulation of some important angiogenic factors, such as fibroblast growth factor 2 (FGF2), IL6, and CCL2, in Puma-deficient retinae ( Figures 2G-2I ). Together, these data demonstrate that retinal microglia contribute to retinal angiogenesis by producing important angiogenic factors.
Impaired Angiogenic Response in Puma-Deficient Aortic Ring and Cornea
We subsequently used an aortic ring and a cornea pocket assay to investigate whether Puma deficiency affected angiogenesis in other tissues. In the aortic ring assay, Puma deficiency nearly completely abolished VEGF-and FGF2-induced angiogenesis ( Figures 3A and 3B Figure 3E ). Thus, Puma deficiency impaired angiogenesis in other tissues than the retina.
Puma Deficiency Inhibited Choroidal Neovascularization
We next tested whether Puma deficiency affected choroidal neovascularization (CNV) using Puma-deficient mice and Puma shRNA in a laser-induced CNV model. Puma deficiency decreased CNV area by more than 50% ( Figure 3F ). Moreover, intravitreous injection of Puma shRNA, which decreased PUMA expression by about 60% in the retinae and choroids (Figure S3D ), inhibited CNV formation ( Figure 3G ) and decreased the number of CNV-associated Iba1 + microglia ( Figure 3G ). Indeed, real-time PCR displayed decreased expression of different microglia markers, including Iba1 ( Figure 3H ), CD11b, and CD68 ( Figure S3E ) in the Puma shRNA-treated choroids and retinae. Consistent with the reduced CNV areas by Puma shRNA treatment, the expression of many important angiogenic genes markedly decreased in the Puma shRNA-treated choroids and retinae ( Figure S3F ).
PUMA Is Required for Vascular and Microglia Cell Proliferation and Survival
To investigate the cellular mechanisms underlying the effect of PUMA, we explored whether PUMA affected vascular and microglia cell proliferation and survival. In cultured primary retinal microglia, brain endothelial cells (ECs), and aortic artery smooth muscle cells (SMCs), Puma deficiency decreased cell proliferation and survival under different conditions ( Figures 4A-4C Figures S4G and S4H ). We next engaged several more direct methods than the MTT assay to further verify the proliferative and survival effect of PUMA, such as the BrdU assay, the trypan blue exclusion assay, and the LIVE/DEAD viability/cytotoxicity assay. Using the BrdU assay, we found that overexpression of PUMA increased cell proliferation in the primary microglia cells ( Figures 4I and S4I) , TR-iBRB, and HUVECs at different time points ( Figures 4J, 4K , S4E, and S4F), whereas PUMA deficiency by shRNA knockdown inhibited proliferation of primary microglia ( Figures 4L and S4J ). To investigate the survival effect of PUMA, we treated the cells with mitomycin C to suppress cell proliferation, and performed a trypan blue exclusion assay and a LIVE/DEAD viability/cytotoxicity assay. Using these two methods, we found that overexpression of PUMA increased survival of primary microglia ( Figures  4M and S4I ), whereas Puma shRNA treatment decreased their survival ( Figures 4N, 4O , and S4J). Thus, apart from the MTT assay, several additional assays demonstrated a proliferative and survival effect of PUMA on microglia and vascular cells. Furthermore, Puma deficiency impaired retinal microglia migration induced by ATP, CCL2, and CCL3 ( Figure 5A ).
Puma Deficiency Impairs Erk Activation and M-CSFR Expression
We subsequently investigated the molecular mechanisms underlying the actions of PUMA. Puma deficiency markedly attenuated Erk activation under different conditions in primary brain vascular endothelial ( Figure 5B ) and retinal microglia cells ( Figure 5C ). Consistently, Puma knockdown by shRNA inhibited Erk activation in primary microglia ( Figures 5D, S4A , and S4B). In addition, the expression level of macrophage colony stimulating factor receptor (M-CSFR), a factor mainly expressed by microglia/macrophages and critical for angiogenesis (Kubota et al., 2009) , considerably decreased in Puma-deficient microglia and retinae ( Figures 5E and 5F ). This observation is consistent with the finding of less microglia in Puma-deficient retinae. Moreover, the expression levels of M-CSFR in cultured primary microglia in vitro and in mouse retinae in vivo decreased after Puma shRNA treatment ( Figures 5G, 5H , S2A, and S2B). Importantly, Puma gene delivery by in vivo transfection of PUMA-expressing DNA plasmids into P1 Puma-deficient mouse retinae increased retinal microglia numbers ( Figures 5I, 5J , and S5A-S5C), retinal vascular branch points and vascular area ( Figures 5K and 5L) , and restored M-CSFR expression and Erk activation at P6 ( Figure 5M ). Thus, PUMA is critically required for Erk activation and M-CSFR expression, both of which are important for angiogenesis and microglia proliferation, survival, and migration (Liva et al., 1999; Otero et al., 2009; Reddy et al., 2009; Sasaki et al., 2000) .
PUMA Is Required for Vascular and Microglia Cell Autophagy
Our finding that PUMA is required for vascular and microglia cell proliferation and survival was unexpected, as it contradicted the common belief that PUMA is an essential apoptosis inducer. To understand this paradox, we investigated whether PUMA affected autophagy, a critical regulatory process of cell survival and proliferation, under conditions of metabolic stress (Rabinowitz and White, 2010) . The intensity of the LC3II band (16 kDa) was used as a marker for autophagy using western blots. Puma deficiency markedly impaired autophagy under various conditions in primary retinal microglia ( Figure 6A ), brain vascular ECs ( Figure 6B ) and aortic artery SMCs ( Figure 6C ), as demonstrated by the disappearance or reduced intensity of the 16 kDa LC3II band (Figures 6A-6C) . Consistently, Puma shRNA (D) Puma deficiency by genetic deletion impaired VEGF-induced angiogenesis in a cornea pocket assay (n = 8, p < 0.05).
(E) Immunofluorescence staining showed fewer CD11b + cells in the Puma-deficient corneas (n = 8 or 6, p < 0.05).
(F) IB4 immunofluorescence staining (red) showed that Puma deficiency decreased CNV area by more than 50% in a laser-induced CNV model (n = 8, p < 0.001).
(G) IB4 immunofluorescence staining (red) showed that Puma shRNA treatment inhibited CNV formation (n = 9, p < 0.05) and decreased the number of Iba1 + CNVassociated microglia (n = 8, p < 0.05).
(H) Real-time PCR revealed decreased expression of the microglia marker Iba1 in Puma shRNA-treated choroids (n = 6, p < 0.001). Scale bars represent 200 mm (A, B), 100 mm (C, E-G), or 500 mm (D). Data are represented as mean ± SEM; *p < 0.05, ***p < 0.001. See also Figure S3 and Table S3 .
treatment markedly inhibited autophagy in the RAW264.7 macrophage cells ( Figures 6D and S6A ), whereas overexpression of PUMA increased autophagy in RAW264.7 cells and primary retinal microglia ( Figures 6E, 6F , S6B, and S6C). Moreover, immunofluorescence staining showed that overexpression of PUMA in primary retinal microglia increased autophagy as demonstrated by the increased LC3 + dots ( Figures 6G [arrows] and S6C), whereas Puma deficiency decreased autophagy in primary brain ECs (less LC3 + dots) ( Figure 6H , arrows).
PUMA-Induced Autophagy Requires Erk Activation
Because Puma deficiency attenuated Erk activation ( Figures 5B-5D ), we hypothesized that PUMA-induced autophagy might require Erk activation and tested this hypothesis. Treatment with an Erk1/2 inhibitor U0126 inhibited Erk activation and PUMA-induced autophagy in primary microglia (Figures 6I and S6C) and TR-iBRB ( Figures 6J and S4E ). Consistently, immunofluorescence staining showed that while PUMA overexpression induced autophagy in the TR-iBRB cells ( Figure 6K , middle panel, arrows showing the increased LC3 + dots), U0126 treatment abolished PUMA-induced autophagy ( Figure 6K , right panel, decreased LC3 + dots). Moreover, western blot showed that U0126 treatment inhibited Erk activation and autophagy (reduced intensity of the LC3II band) in the aortic SMCs (Figure 6L) . We next investigated whether Erk activation was responsible for the greater survival rate of the wild-type microglia and vascular cells. We found that U0126 and A6355 (another Erk inhibitor) treatment completely abolished the increased survival rate of the wild-type microglia and vascular cells ( Figures  6M-6O) . Thus, our data demonstrated that Erk activation was required for PUMA-induced autophagy and survival of vascular and microglia cells.
PUMA Deficiency Decreased Vascular and Microglia Cell Cytoplasmic Calcium Levels
It is known that in fibroblasts PUMA, but not Noxa, increases cytosolic calcium levels (Shibue et al., 2006) . Importantly, cytoplasmic calcium plays a critical role in inducing autophagy (Høyer-Hansen et al., 2007; Swerdlow and Distelhorst, 2007) and Erk activation (Agell et al., 2002; Schmitt et al., 2004) . We therefore studied whether PUMA affected intracellular calcium levels in vascular and microglia cells. Using fluorescent Fluo-4 acetoxymethyl (Fluo-4AM) as an indicator of cytosolic calcium, we found that Puma deficiency reduced cytosolic calcium levels under a steady-state condition and upon ATP or mechanical stimulation in primary retinal microglia ( Figure 7A ), primary vascular ECs ( Figure 7B ), and primary vascular SMCs (Figure 7C) . Consistently, Puma knockdown by RFP-Puma shRNA decreased cytosolic calcium levels in primary retinal microglia in the RFP-Puma shRNA expressing cells ( Figure 7D , arrows in the right panel). These data demonstrated that PUMA plays a critical role in regulating cytosolic calcium levels, which is essential in modulating Erk activation and autophagy.
DISCUSSION
Our findings that PUMA is critically required for the survival and proliferation of vascular and microglia cells and plays important roles in angiogenesis are highly unexpected, given that PUMA has been considered as an essential apoptosis inducer for more than 10 years . We further revealed that the survival/proliferative effect of PUMA was achieved by induction of autophagy, a critical mechanism for cells to respond to metabolic stress in order to survive, proliferate, and migrate (Fan et al., 2010) . Mechanistically, we revealed that PUMA plays a critical role in regulating Erk activation and intracellular calcium level. Our data thus revealed an unexpected function of PUMA as a survival, proliferative, and angiogenic factor that contradicts the known apoptosis-inducing role of PUMA.
Little was known about the function of PUMA in vascular and microglia cells, even though the proapoptotic effect of PUMA on other types of cells has been studied intensively. Indeed, although Puma deficiency in mice decreased apoptosis in fibroblasts and lymphocytes (Villunger et al., 2003) , the same apoptotic effect has not been observed on vascular or microglia cells. In this study, we found that PUMA is abundantly expressed in vascular and microglia cells. In vitro, Puma deficiency impaired proliferation and survival of cultured vascular and microglia cells, and nearly completely abolished the angiogenic response of mouse aortic rings. In vivo, Puma deficiency by genetic deletion or shRNA treatment decreased blood vessel and microglia density in retina and brain, and suppressed angiogenesis in different animal models. Consistently, Puma gene delivery promoted cell proliferation and survival in vitro, and increased blood vessel and microglia density in vivo. Interestingly, PUMA was recently reported to be critically required for tumorigenesis (Michalak et al., 2010) , whereas other apoptotic genes, such as p53 and Noxa, inhibited tumorigenesis (Michalak et al., 2010) . Although a different mechanism underlying the tumorigenic activity of PUMA was suggested, it nevertheless indicated a unique growth-promoting function of PUMA, at least under certain conditions. In addition, while retinal microglia density and angiogenesis were reduced in Puma-deficient mice, the retinal astrocytes appeared to be normal, demonstrating a cell-specific effect of PUMA. Indeed, other investigators have also reported a cell-specific effect of PUMA (Qiu et al., 2008) .
Another important finding in this study is the critical role of PUMA in inducing vascular and microglia cell autophagy by regulating Erk activation and cytosolic calcium levels (Figure 7E ). Autophagy is a homeostatic cellular recycling mechanism essential for cell survival, proliferation, and migration (Fan et al., 2010; Rabinowitz and White, 2010) . It is especially crucial when the cells are under metabolic stress, such as hypoxia, even though uncontrolled autophagy can eventually lead to cell death. Autophagy has been shown to be critically required for macrophage migration and T cell proliferation (Kadandale et al., 2010) . In this study, loss of PUMA by gene deletion or shRNA markedly inhibited autophagy and impaired Erk activation in microglia, vascular ECs, and SMCs, whereas Puma gene delivery increased autophagy and Erk activation. Calcium signaling plays a critical role in Erk activation (Agell et al., 2002; Schmitt et al., 2004) and autophagy induction (Høyer-Hansen et al., 2007; Swerdlow and Distelhorst, 2007) . Because shRNA-mediated loss of PUMA markedly decreased cytosolic calcium levels in microglia, the effect of PUMA on Erk activation and autophagy may be mediated by its regulatory effect on calcium signaling. 
y a s s a T T M
The previously unrecognized angiogenic effect of PUMA is surprising, because no other BH3-only protein family member has been shown to display such a function. It is reported that microglia play crucial roles in angiogenesis, at least in part, by producing potent angiogenic factors (Checchin et al., 2006; Liu et al., 2005; Yamaguchi et al., 2011) . In this study, we found that the expression levels of many important angiogenic factors were significantly reduced. Thus, apart from its direct effect on vascular cells, PUMA plays an important role in angiogenesis also by ensuring adequate microglia density and sufficient amount of angiogenic factors. Our finding that PUMA is a survival, proliferative, and angiogenic factor may have important therapeutic implications. Because of its potent apoptotic activity, PUMA has been considered as a promising therapeutic molecule for cancer treatment (Ito et al., 2005) . In addition, the therapeutic potential of targeted PUMA inhibition to suppress apoptosis for the treatment of degenerative diseases has attracted considerable research interest . However, our current findings suggest that Puma gene delivery or inhibition may lead to undesired effects on vascular and immune systems and warrant more careful investigations.
Although we have demonstrated an unexpected function of PUMA using comprehensive systems and approaches, outstanding questions remain. For example, we currently cannot explain how PUMA regulates cytosolic calcium levels and Erk activation. Also, it remains elusive how the functional property of PUMA is regulated to fulfill its autophagy or apoptotic activities in different cells or under different conditions. It is possible that there may be intermediate context-dependent molecules mediating the different activities of PUMA. Moreover, although our data demonstrated a cell-autonomous function of PUMA in microglia and vascular cells, this does not rule out the possibility that programed elimination of certain types of retinal cells (e.g., neurons) by PUMA during development might signal the proliferation of retinal microglia and vascular cells. Future studies are needed to answer these questions. In summary, our data revealed an angiogenic activity of PUMA, which can act as a survival and proliferative factor by modulating autophagy, and demonstrated an unexpected complexity of PUMA function.
EXPERIMENTAL PROCEDURES
Animals, Intraocular Injections, and Tissues
The mice used and the eye tissue isolation are described in the Extended Experimental Procedures. For Puma knockdown in vivo, 2 mg/0.5 ml/eye of pLKO.1 DNA plasmid encoding the mouse Puma shRNA or the pLKO.1 empty vector (Open Biosystems) together with the in vivo-jetPEI reagent (Polyplustransfection) was injected into P1 mouse vitreous according to the manufacturer's instructions. For Puma gene delivery in vivo, 2 mg/0.5 ml/eye of pCMV6-AC-RFP vector encoding mouse PUMA or the pCMV6-AC-RFP vector without PUMA (OriGene Technologies) with the in vivo transfection reagent was injected into P1 mouse vitreous. In vivo microglia depletion was described previously (Checchin et al., 2006) .
Immunofluorescent Staining and Retinal Image Analysis
Immunofluorescent staining and retinal image analysis are described in the Extended Experimental Procedures. The reagents used for staining were: isolectin GS-B4 (IB4, Invitrogen), DAPI (Invitrogen), rabbit anti-mouse CD11b (BD PharMingen), rat anti-CD31 (PharMingen), rabbit anti-iba1 (Wako), rabbit anti-PUMA (Cell Signaling), goat anti-mouse PDGFRa (R&D), mouse anti-GFAP (Sigma-Aldrich), rabbit anti-LC3B (Novus Biologicals), and the Alexa Fluor fluorescence-conjugated IgGs (Invitrogen).
Western Blot and Real-Time PCR Western blot was performed as described . The antibodies used were: rabbit anti-PUMA (Cell Signaling, Sigma-Aldrich), rabbit anti-FGF2 (Santa Cruz), rat anti-IL6 (Biolegend), armenian hamster anti-CCL2 (Biolegend), rabbit anti-LC3B (Novus Biologicals), rabbit anti-M-CSFR (Cell Signaling), mouse anti-p44/42 MAPK (Erk1/2) (Cell Signaling), and rabbit anti-Phospho-p44/42 MAPK (Erk1/2) (Cell Signaling). Monoclonal anti-b-actinperoxidase (Sigma-Aldrich) was used as an internal control. Real-time PCRs were performed in triplicates as described and repeated at least once. Primers used are listed in Table S3 .
Cornea Pocket and Aortic Ring Assays
The mouse cornea pocket assay was performed as described (Li et al., 2008; Zhang et al., 2009) . Human VEGF 165 (PeproTech) of 160 ng/pellet/cornea was used in the experiments. CD11b + microglia density within the active angiogenic area was assessed using an Imager Z1 microscope and AxioVision software (Carl Zeiss). The aortic ring assay was performed as described using human VEGF 165 and FGF2 (100 ng/ml, R&D Systems).
Images of the aortic rings were taken on day 7 after implantation and microvessels analyzed as described . CD11b + cells were analyzed by immunostaining.
Laser-Induced Choroidal Neovascularization Model
The CNV model was performed as described (Zhang et al., 2009 ). Eight to tenweek-old mice were used for experiments. A total of 1 mg/eye of pLKO.1 mouse Puma shRNA plasmid or the control pLKO.1 plasmid without the Puma shRNA (Open Biosystems) together with the transfection reagent in vivojetPEI (Polyplus-transfection) was injected into the mouse vitreous according to the manufacturer's instructions. CNV area was analyzed 1 week after laser treatment using IB4 staining. Microglia density was analyzed by immunofluorescence staining using Iba1 as a marker.
Primary Cell Isolation and Cell Culture
Primary mouse retina and brain microglia cells, astrocyte, brain ECs, and aortic artery SMCs were isolated and cultured as described (Matsubara et al., 2000; Saijo et al., 2009; Seidel et al., 1991) . Cells within ten passages were used for experiment. The immortalized TR-iBRB and RGC5 were cultured as described (Li et al., 2008) . The HUVEC (Lonza) and RAW264.7 macrophage cells (ATCC) were cultured according to the manufacturer's instructions.
Intracellular Calcium Assay
The intracellular calcium assay was performed according to the manufacturer's instructions (Invitrogen) and is described in the Extended Experimental Procedures. The primary retinal microglia cells transfected with a pRFP-C-RS vector encoding the mouse Puma shRNA or the pRFP-C-RS vector encoding a noneffective 29-mer scrambled shRNA (OriGene Technologies) were used for experiments 3 days after transfection. Figure S6 .
Proliferation, Survival, and Cell Chemotaxis Assay Several methods were used to assess cell proliferation and survival, including an MTT assay, a DAPI-TUNEL staining method, a BrdU assay, a trypan blue exclusion assay, and a LIVE/DEAD viability/cytotoxicity assay (Invitrogen). Primary cells isolated from six to eight mice were pooled and cultured for experiments. Serum-free medium was used for EC, SMC, and 293FT cell starvation. The Hank's balanced salt solution (Invitrogen) was used for microglia starvation. For the MTT assay, experiments were performed according to the manufacturer's protocol (Invitrogen). The Erk inhibitor A6355 and Mek inhibitor U0126 (10 mM each, Sigma) were used to block the Erk pathway using (E) PUMA is required for the survival and proliferation of vascular and microglia cells by regulating intracellular calcium level, Erk activation, and autophagy, which is essential for cell survival, proliferation and migration, particularly, under conditions of metabolic stress. Scale bars represent 20 mm. Data are represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001. 0.1% DMSO (Sigma-Aldrich) as a control. A DAPI (Invitrogen) and a TUNEL (Roche) staining method was used to count the number of viable and apoptotic cells in 24 fields (450 mm 3 350 mm each) each assay and the mean value calculated. Experiments were performed in triplicate under a normoxic or hypoxic condition (1% oxygen) and repeated at least once, and representative data presented. For the BrdU proliferation assay, cells were cultured in complete medium and cell proliferation assessed using a cell proliferation ELISA BrdU colorimetric kit according to the manufacturer's protocol (Roche). For cell survival assay, primary retinal microglia cells were treated with mitomycin C (Sigma, 50 mg/ml) in serum-free medium for 2 hr to inhibit cell proliferation and then cultured in serum-free medium with repeated mitomycin C treatment every 24 hr. After 3 days, the viable cells were counted using a trypan blue exclusion method. The viable and dead cells were also stained and analyzed using a LIVE/DEAD viability/cytotoxicity assay kit (Invitrogen). The pLKO.1 Puma shRNA plasmid and the control pLKO.1 plasmid without the Puma shRNA (Open Biosystems), and the pCMV6 Puma gene expression plasmid and the control pCMV6 plasmid without the Puma gene (OriGene Technologies), were transfected into the cells using a SuperFect reagent (QIAGEN) according to the manufacturer's protocol. Puromycin (Sigma) or G418 (Sigma) was used for selection according to the manufacturer's protocol. Three biological repeats were performed for each experiment and the mean value from the repeats is presented. Microglia chemotaxis assay was performed as described (Ma et al., 2009 ) using the chemoattractants ATP (50 mM, Sigma), CCL2 (100 ng/ml, R&D), and CCL3 (50 ng/ml, R&D).
Statistical Analysis
Two-tailed Student's t test was used for statistical analysis. Difference was considered statistically significant when p < 0.05. Results are represented as mean ± SEM of the number of determinations.
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